On site inspection of low molecular weight heparin calcium API of Dongcheng pharmaceutical

According to the information on January 26 on the website of the State Food and Drug Administration (CFDA), Dongcheng pharmaceutical's key product, low molecular weight heparin calcium API, has entered the drug registration and production site for inspection this month According to the drug declaration process, after the completion of the on-site inspection, there are still three in one comprehensive review and submission to CFDA for signature, which is expected to be approved within the year Previously, Dongcheng pharmaceutical industry insiders had said that low molecular weight heparin calcium is the key variety developed by the company according to EU standards Once the production approval is obtained, it will be listed and promoted immediately According to the public information, low molecular weight heparin calcium is also known as natroxobin calcium, which was approved by Dongcheng pharmaceutical in May 2007 At present, the product has 4 API manufacturers and 5 preparation manufacturers in China Dongcheng Pharmaceutical Co., Ltd is mainly engaged in heparin sodium API and chondroitin sulfate At present, the company is actively transforming to preparation business The company says that it will build a cardio cerebrovascular product line based on the existing and under research low molecular weight heparin products of the company, strive to achieve the raw material medicine and preparation business within 2-3 years, and keep pace with the industry pattern in terms of profit contribution.